204 related articles for article (PubMed ID: 17203978)
1. Protein expression in a Drosophila model of Parkinson's disease.
Xun Z; Sowell RA; Kaufman TC; Clemmer DE
J Proteome Res; 2007 Jan; 6(1):348-57. PubMed ID: 17203978
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease.
Xun Z; Sowell RA; Kaufman TC; Clemmer DE
Mol Cell Proteomics; 2008 Jul; 7(7):1191-203. PubMed ID: 18353766
[TBL] [Abstract][Full Text] [Related]
3. Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease.
Xun Z; Sowell RA; Kaufman TC; Clemmer DE
J Proteome Res; 2007 Sep; 6(9):3729-38. PubMed ID: 17683129
[TBL] [Abstract][Full Text] [Related]
4. Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease.
Xun Z; Kaufman TC; Clemmer DE
J Proteome Res; 2008 Sep; 7(9):3911-21. PubMed ID: 18683964
[TBL] [Abstract][Full Text] [Related]
5. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages.
Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K
Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164
[TBL] [Abstract][Full Text] [Related]
6. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease.
Scherzer CR; Jensen RV; Gullans SR; Feany MB
Hum Mol Genet; 2003 Oct; 12(19):2457-66. PubMed ID: 12915459
[TBL] [Abstract][Full Text] [Related]
8. Examining the proteome of Drosophila across organism lifespan.
Sowell RA; Hersberger KE; Kaufman TC; Clemmer DE
J Proteome Res; 2007 Sep; 6(9):3637-47. PubMed ID: 17696518
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.
Olsen AL; Feany MB
Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834
[TBL] [Abstract][Full Text] [Related]
10. Roles of α-Synuclein and Disease-Associated Factors in
Suzuki M; Sango K; Nagai Y
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163450
[TBL] [Abstract][Full Text] [Related]
11. The neuroprotective effect of fullerenols on a model of Parkinson's disease in Drosophila melanogaster.
Golomidov I; Bolshakova O; Komissarov A; Sharoyko V; Slepneva Е; Slobodina A; Latypova E; Zherebyateva O; Tennikova T; Sarantseva S
Biochem Biophys Res Commun; 2020 Mar; 523(2):446-451. PubMed ID: 31879013
[TBL] [Abstract][Full Text] [Related]
12. Yeast red pigment modifies cloned human α-synuclein pathogenesis in Parkinson disease models in Saccharomyces cerevisiae and Drosophila melanogaster.
Nevzglyadova OV; Mikhailova EV; Artemov AV; Ozerova YE; Ivanova PA; Golomidov IM; Bolshakova OI; Zenin VV; Kostyleva EI; Soidla TR; Sarantseva SV
Neurochem Int; 2018 Nov; 120():172-181. PubMed ID: 30099122
[TBL] [Abstract][Full Text] [Related]
13. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
[TBL] [Abstract][Full Text] [Related]
14. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.
Singh S; Khayachi A; Milnerwood AJ; DeMarco ML
J Parkinsons Dis; 2020; 10(2):613-621. PubMed ID: 32083592
[TBL] [Abstract][Full Text] [Related]
16. Modeling Parkinson's disease in adult Drosophila.
Dabool L; Juravlev L; Hakim-Mishnaevski K; Kurant E
J Neurosci Methods; 2019 Jan; 311():89-94. PubMed ID: 30336223
[TBL] [Abstract][Full Text] [Related]
17. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
Haywood AF; Staveley BE
BMC Neurosci; 2004 Apr; 5():14. PubMed ID: 15090075
[TBL] [Abstract][Full Text] [Related]
18. α-synuclein impairs autophagosome maturation through abnormal actin stabilization.
Sarkar S; Olsen AL; Sygnecka K; Lohr KM; Feany MB
PLoS Genet; 2021 Feb; 17(2):e1009359. PubMed ID: 33556113
[TBL] [Abstract][Full Text] [Related]
19. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M
Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340
[TBL] [Abstract][Full Text] [Related]
20. Monitoring α-Synuclein Proteotoxicity in Drosophila Models.
Szabo A; Tofaris GK
Methods Mol Biol; 2019; 1948():199-208. PubMed ID: 30771179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
